| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J R Abbott | |
| J K Coleman | |||
| J K Yamamoto | |||
| M P Sanou | |||
| P2860 | cites work | Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 |
| Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. | Q39358695 | ||
| Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. | Q39358702 | ||
| Perspectives on FIV vaccine development | Q41596962 | ||
| AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection | Q43135807 | ||
| HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection | Q44594584 | ||
| Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine | Q45406970 | ||
| Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host | Q45789424 | ||
| Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. | Q45938142 | ||
| Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. | Q51977322 | ||
| Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence | Q58361924 | ||
| Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV | Q74523548 | ||
| Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection | Q78551235 | ||
| Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand | Q81488462 | ||
| RV144: old vs. new | Q84134792 | ||
| Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1 | Q84444040 | ||
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT. | Q30763125 | ||
| HIV-1 vaccine development after STEP. | Q33642318 | ||
| Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus | Q33769283 | ||
| Live attenuated AIDS viruses as vaccines: promise or peril? | Q33776149 | ||
| Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells | Q33981572 | ||
| Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine | Q34157802 | ||
| Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. | Q34335632 | ||
| FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review | Q34529430 | ||
| Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? | Q35001377 | ||
| HIV vaccine design: insights from live attenuated SIV vaccines | Q36343536 | ||
| Advances in FIV vaccine technology | Q36634847 | ||
| Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans | Q36971813 | ||
| Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens | Q37263878 | ||
| Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells | Q37295542 | ||
| Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans | Q37372794 | ||
| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis | Q37413781 | ||
| Feline immunodeficiency virus model for designing HIV/AIDS vaccines | Q37704546 | ||
| P433 | issue | 3-4 | |
| P921 | main subject | HIV/AIDS | Q12199 |
| P304 | page(s) | 246-254 | |
| P577 | publication date | 2011-06-12 | |
| P1433 | published in | Veterinary Immunology and Immunopathology | Q7923704 |
| P1476 | title | Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine | |
| P478 | volume | 143 |
| Q37123133 | Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects |
| Q82718989 | HIV-1: from escapism to conservatism |
| Q64249816 | Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses |
| Q54984932 | Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine. |
| Q47562618 | Major histocompatibility complex class I (FLA-E*01801) molecular structure in domestic cats demonstrates species-specific characteristics in presenting viral antigen peptides. |
Search more.